U.S.-made KSMs drive pharma efficiency, Eastman Kodak asserts

U.S.-made KSMs drive pharma efficiency, Eastman Kodak asserts
Eastman Kodak launches U.S.-made KSMs

Eastman Kodak is expanding its role in the pharmaceutical sector by offering high-quality, U.S.-made key starting materials (KSMs) that support drug companies in accelerating innovation and reducing risk.

The company highlights that its expertise in chemistry and commitment to domestic manufacturing allows pharmaceutical firms to maintain consistent quality standards while optimizing production processes. Eastman Kodak's focus on operational excellence positions it as a reliable partner for companies seeking stability in their supply chains.

Kodak’s continued diversification into pharmaceuticals builds on a foundation of chemical expertise long recognized for driving innovation through its legacy in film and imaging technologies. This approach reflects the company’s broader strategy, as previously demonstrated in leveraging its film expertise for growth in printing and materials (innovation through decades of film expertise), while also placing value on operational excellence supported by employee recognition initiatives (contribution advancing innovation and manufacturing).

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.